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Background: Women affected by polycystic ovary syndrome (PCOS) are known to be at 
higher risk of cardiovascular disease. The aim of this study was to identify the artery that first 
is affected by early pre-atherosclerotic changes in PCOS.
Methods: Twenty-nine women with PCOS aged 17 to 27 years and 26 healthy nonhyperandrogenic 
volunteers with regular menses (control women) aged 16 to 28 years were enrolled. All PCOS 
patients were overweight or obese (body mass index [BMI]  25). Diagnosis of PCOS was 
performed in line with the 2003 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop 
Group. Accordingly, PCOS was defined when at least two of the following three features were 
present after exclusion of other etiologies: 1) oligomenorrhea and or anovulation; 2) hyperan-
drogenism and/or hyperandrogenemia; and 3) polycystic ovaries visible at ultrasound. Androgen 
excess or related disorders were excluded. The intima-media thickness (IMT) of common carotid 
arteries and common femoral arteries and the anteroposterior diameter of the infrarenal abdominal 
aorta were measured by ultrasound. Lutenizing hormone (LH), follicle-stimulating hormone 
(FSH), estradiol, total testosterone, androstenedione, and sex hormone-binding globulin (SHBG) 
serum levels were measured between the 3rd and the 6th day of spontaneous or progestin-induced 
menstrual cycle. Our study was performed in the absence of any medical treatment.
Results: Women with PCOS showed a higher LH to FSH ratio (p  0.01), increased fasting 
insulin (p  0.001), total testosterone (p  0.001), and androstenedione (p  0.001) levels, and 
lower SHBG concentrations (p  0.001) compared to control women. BMI and waist-to-hip 
ratio were also higher in women with PCOS (p  0.000 and p  0.001, respectively). Women 
with PCOS also showed increased total cholesterol (p  0.001), triglyceride (p  0.001), and 
apolipoprotein B (p  0.001) levels. Vascular data showed women with PCOS had a higher 
anteroposterior diameter than control women (p  0.005). However, when analysis of covariance 
was performed and BMI was entered into the model as a covariate, anteroposterior diameter 
did not maintain a significant association with PCOS.
Conclusion: This study shows that anteroposterior diameter of the infrarenal abdominal aorta, 
but not IMT of common carotid arteries or common femoral arteries, is higher in women with 
PCOS than in women without this disease. This represents the earliest atherosclerotic change 
in women with PCOS. However, this alteration seems to be due to body weight secondary to 
PCOS and not due to PCOS per se.
Keywords: polycystic ovary syndrome, antero-posterior diameter, infrarenal abdominal aorta, 
intimia-media thickness
Introduction
Polycystic ovary syndrome (PCOS) is a clinical association of anovulation and 
hyperandrogenism, but it is often associated with irregular menses, infertility, acne, Vascular Health and Risk Management 2009:5 562
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and hirsutism.1–4 Although it is important to recognize and 
address these clinical problems, attention has also turned to 
the risk of diabetes and cardiovascular disease5 due to central 
obesity,6,7 dyslipidemia (low high-density lipoprotein [HDL] 
and higher cholesterol and triglyceride levels),6,8 hyperten-
sion,6 endothelial dysfunction,9 and insulin resistance.10,11
Shaw and colleagues recently reported that women with 
clinical features of PCOS have five years lower cardiovascular 
event-free survival than women without clinical features of 
PCOS.12 The mechanisms responsible for higher cardiovas-
cular risk are dyslipidemia, consisting of higher triglycerides, 
lower HDL cholesterol, and small increases in low-density 
lipoprotein (LDL) particles, insulin resistance, compensatory 
hyperinsulinemia, central obesity, and androgen excess.13,14
Vascular preclinical abnormalities have been recently 
demonstrated in women with PCOS by using Doppler 
ultrasound. In particular, several studies found an increased 
intima-media thickness (IMT) of common carotid artery in 
PCOS patients.15–17 To the best of our knowledge, there are no 
data concerning the IMT of common femoral arteries and the 
anteroposterior diameter of abdominal aorta in women affected 
by PCOS. Moreover, it is not known which is the earliest 
alteration in these patients: common carotid artery thickening, 
common femoral artery thickening, or an enlargement of the 
anteroposterior diameter of the infrarenal abdominal aorta.
Wilmink and colleagues have shown that the use of ultra-
sounds to measure the infrarenal aortic diameter is attractive 
as it is rapid, cheap, and noninvasive.18 These characteris-
tics allow serial testing before proceeding with an invasive 
procedure. A serial scanning can increase the detection rate 
and decrease the false positive rate. The good accuracy of 
infrarenal aortic diameter measurements by ultrasound makes 
this method acceptable for clinical decision-making.
The present study examines whether 1) the IMT of com-
mon carotid arteries and common femoral arteries is higher 
in women with PCOS than in those without this disease 
(control), 2) the anteroposterior diameter of abdominal aorta 
is different between the two groups, and 3) to identify in 
patients with PCOS which is the earliest alteration: common 
carotid artery thickening, common femoral artery thickening, 
or enlargement of the anteroposterior diameter of the infra-
renal abdominal aorta. Twenty-nine young women affected 
by PCOS and not taking any drugs were investigated.
Material and methods
study population
Twenty-nine patients with PCOS aged 17 to 27 years were 
consecutively enrolled in the Department of Obstetrics and 
Gynecology, General Hospital Policlinico of Bari, Italy. 
Diagnosis of PCOS was performed in line with the 2003 
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus 
Workshop Group.1 PCOS was defined when at least two 
of the following three features were present after exclusion 
of other etiologies: 1) oligomenorrhea and or anovulation; 
2) hyperandrogenism and/or hyperandrogenemia; and 3) 
polycystic ovaries visible at ultrasound. All patients were 
overweight or obese (body mass index [BMI]  25) and 
none of them had been treated with hormones in the previ-
ous 12 months.
The control group consisted of twenty-six healthy vol-
unteers aged 16 to 28, with regular menses (cycle length, 
28.1 ± 1.3 days), and normal ultrasonographic appearance 
of ovaries.
Additional endocrine diseases (hypothyroidism, hyper-
thyroidism, hyperprolactinemia, Cushing’s syndrome, and 
congenital adrenal hyperplasia screening) were excluded by 
hormone measurements in all PCOS and control women, and 
all of them had normal renal and hepatic function.
Hormonal assays, lipid analysis, and ultrasonography 
were performed in the early follicular phase, between the 
3rd and the 6th day of the menstrual cycle. Menstruation 
was spontaneous or progestin-induced in women with PCOS, 
spontaneous in all control women, and progestin-induced in 
oligomenorrhoic women.
Hirsutism was evaluated according to the Ferriman–Gall-
wey score in all women and anthropometric parameters 
obtained by measurement of height, weight, and waist and 
hip circumferences. BMI was computed as the ratio of weight 
divided by height squared (kg/m2), while the waist-to-hip 
ratio (WHR) was calculated as the ratio of waist circumfer-
ence divided by hip circumference. All women were screened 
with a standard two-hour oral glucose tolerance test (OGTT). 
None of the control women showed fasting hyperinsulinemia 
(15 µU/ml) or glucose intolerance. Only two women 
with PCOS showed glucose intolerance and none of them 
showed diabetes. Blood pressure was recorded on at least 
three different occasions using a mercury manometer with 
an appropriate cuff size.
Hormonal data and biochemical 
evaluation
Blood samples for hormonal data were drawn between 
8.00 am and 9.00 am after an overnight fast on the same 
day of the ultrasound. Serum lutenizing hormone (LH), 
follicle-stimulating hormone (FSH), estradiol (E2), and 
testosterone were measured by enzyme immunoassay kits Vascular Health and Risk Management 2009:5 563
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(Biochemical Immunosystem, Guidonia-Rome, Italy). 
Androstenedione (DiaSorin GMBH, Dusseldorf, Germany), 
insulin (Cis Bio International, Vercelli, Italy), and serum 
sex hormone-binding globulin (SHBG) (Euro-Diagnostica, 
Malmö, Sweden) were determined by using commercially 
available radioimmunoassay (RIA) kits. The intraassay 
and interassay coefficients of variation of all these methods 
did not exceed 10% and 15%, respectively. Serum glucose 
was measured by the glucose oxidase method (Boehringer, 
Ingelheim, Germany). OGTT was performed by administer-
ing 75 g of D-glucose per os and collecting blood samples 
before (0 minutes), and after 30, 60, 90, and 120 minutes 
from oral administration.
Fasting lipid profile included the measurement of total 
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, 
apolipoproteins A-1 (apo A-1) and B (apo B) levels. Fast-
ing serum levels of lipids were measured by commercial 
enzymatic methods (Boehringer Mannheim, Lewes, UK). 
The lipid determinations were made on the supernatants, 
but increased assay sensitivity was achieved by increasing 
the sample volume and adding tribromohydroxybenzoic 
acid to a concentration of 0.5 g/L in the assay reagent. Apo 
A-1 and apo B were measured by rate immunonephelom-
etry (Beckman Instruments, Fullerton, CA, USA). All these 
methods showed intraassay and interassay coefficients of 
variation of 5% and 9%, respectively.
Transvaginal ultrasound of the ovaries
In the morning, during the early follicular phase (cycle day 2, 
3, or 4), a transvaginal ultrasound was performed by means 
of a transvaginal ultrasound scanner (Toshiba Corp., Tokyo, 
Japan) with a 5.0 MHz probe. In each ovary, the total number 
of small follicles (2 to 10 mm) was counted. Enlarged ovary 
with multiple small follicles arranged around an echogenic 
stroma were considered typical ultrasonographic ovarian 
findings.
Vascular ultrasound studies
All PCOS and control women underwent high-definition 
vascular echocardiography to identify the artery that was 
first affected by early atherosclerosis. High-definition vas-
cular echocardiography was performed in PCOS and control 
subjects according to the following protocols.
evaluation of common carotid artery iMT
Ultrasonographic studies of common carotid arteries were 
performed bilaterally by a single observer. The value of 
common carotid arteries that was considered for statistical 
analyses was the mean of right and left measurements. All 
studies were performed with a Hewlett Packard Sonos 1500 
(Hewlett Packard, Avondale, PA, USA) using a 7.5 MHz 
high-resolution probe. IMT was defined as a low-level echo 
grey band that does not project into the arterial lumen. It 
was measured during end-diastole as the distance from the 
leading edge of the second echogenic line of the far walls of 
the distal segment of the common carotid artery, the carotid 
bifurcation, and the initial tract of internal carotid artery on 
both sides. Measurements were performed 0.5, 1, and 2 cm 
below the bifurcation (three measurements on each side), 
and the average measurement was taken as the IMT. IMT 
measurements were always performed in plaque-free arte-
rial segments.
evaluation of common femoral artery iMT
Ultrasonographic studies on common femoral arteries were 
performed bilaterally by a single observer. The value of 
common femoral arteries that was considered for statistical 
analyses was the mean of right and left measurements. All 
studies were performed with a Hewlett Packard Sonos 1500 
(Hewlett Packard) using a 7.5 MHz high-resolution probe. 
IMT was defined as a low-level echo grey band that does not 
project into the arterial lumen. It was measured during end-
diastole as the distance from the leading edge of the second 
echogenic line of the far walls of the distal segment of the 
common femoral artery on both sides. Measurements were 
performed 0.5, 1, and 2 cm below the femoral (profunda 
and superficial; three measurements on each side), and the 
average measurement was taken as the IMT.
evaluation of infrarenal anteroposterior  
diameter of abdominal aorta
Ultrasonographic studies on infrarenal abdominal aorta 
was performed18–20 by a single observer. All studies were 
performed with a Hewlett Packard Sonos 1500 (Hewlett 
Packard) using a 3 MHz high-resolution probe. All patients 
fasted for six hours prior to the ultrasonography. With the 
patient in a supine position, the electronic probe was placed 
one centimeter left of the umbilicus. The best image in long-
axis projection of the abdominal aorta was then obtained. 
The anteroposterior diameter of the aorta was defined as 
the maximal external cross-sectional measurement. It was 
calculated as the distance between the near and the far walls 
of the abdominal aorta. Measurements were performed at 
0.5, 1, and 2 cm above the umbilicus and were expressed in 
centimeters. In our study, the abdominal aorta was nonaneu-
rysmatic in all women.Vascular Health and Risk Management 2009:5 564
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Repeatability and intraobserver variability 
of ultrasound scan measurements
Repeatability and intraobserver variability of all ultrasound 
scan measurements were evaluated by means of intraclass 
correlation coefficient of 0.90. In particular, anteroposte-
rior diameter showed good reproducibility with an intraclass 
correlation coefficient of 0.92.
statistical methods
Results are presented as mean and standard deviation (SD) 
for all parameters. Variables with a skewed distribution 
(insulin, triglycerides, etc) were logarithmically transformed 
before any statistical analyses to improve the approximation 
to a Gaussian distribution. Differences between women with 
PCOS and the control group were performed by an unpaired 
Student t-test. Analysis of covariance was performed and 
corrected for other clinical variables. P values of 0.05 were 
considered statistically significant. Statistical analyses were 
performed by using STATISTICA 6.1 software (StatSoft 
Inc., Tulsa, OK, USA).
Results
General, anthropometric, hormone, and metabolic character-
istics of women with PCOS and control subjects are reported 
in Table 1. The groups were of similar age and all women 
were without any previous hormonal treatment, but differed 
significantly in most of the other parameters.
Compared to control women, women with PCOS had 
higher BMI, WHR, systolic and diastolic blood pressure 
levels, and higher fasting insulin, total and LDL-cholesterol, 
apo B, and triglyceride levels. HDL and apo A1 showed a 
tendency to be lower in women with PCOS. Sex hormones, 
LH, testosterone, and androstenedione levels and LH to FSH 
Table 1 general, anthropometric, and metabolic parameters in PCOs and control women
PCOS (N = 29) Control (N = 26) Statistical significance
Age (years) 22 ± 3.8 22 ± 3.8 ns
Body mass index (kg/m2) 26.3 ± 4.5 20.5 ± 1.6 p  0.001
Waist-to-hip ratio 0.86 ± 0.05 0.71 ± 0.05 p  0.001
systolic blood pressure (mm Hg) 112.6 ± 7.8 107.9 ± 9 p  0.05
Diastolic blood pressure (mm Hg) 72.1 ± 8.5 66.9 ± 8.6 p  0.05
Fasting insulin (µUi/ml) 16.6 ± 3.9 11.6 ± 2.9 p  0.001
Fasting blood glucose (mg/dl) 84.95 + 9.74 82.98 + 5.83 ns
Total cholesterol (mg/dl) 187.8 ± 3.6 160.6 ± 2.3 p  0.001
HDL-C (mg/dl) 53.4 ± 14 59.6 ± 12 ns
LDL-C (mg/dl) 116.4 ± 3.1 106.7 ± 2.5 p  0.001
Triglycerides (mg/dl) 94.5 ± 6.3 65 ± 2.9 p  0.05
Apo A1 (mg/dl) 133.2 ± 16 134.9 ± 22 ns
Apo B (mg/dl) 89.7 ± 2.5 73 ± 2.05 p  0.001
Abbreviations: Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NS, not significant; PCOS, polycystic ovary 
syndrome.
Table 2 sex hormones in PCOs and control women
PCOS (N = 29) Control (N = 26) Statistical significance
LH (mUi/ml) 11.7 ± 4 4.9 ± 2.8 p  0.001
FsH (mUi/ml) 5.2 ± 2 5.4 ± 1.5 ns
LH to FsH ratio 2.6 ± 1.2 1.1 ± 0.7 p  0.01
Testosterone (ng/dl) 68.3 ± 11.9 43.2 ± 10.0 p  0.001
Androstenedione (ng/ml) 3.9 ± 1.2 2.1 ± 0.9 p  0.001
estradiol (pg/ml) 37.6 ± 11.9 40 ± 8.1 ns
sHBg (µg/ml) 1.7 ± 0.6 3.5 ± 1.2 p  0.001
Abbreviations: FSH, follicle-stimulating hormone; LH, serum luteinizing hormone; NS, not significant; SHBG, sex hormone-binding globulin.Vascular Health and Risk Management 2009:5 565
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ratio were higher in women with PCOS, who showed lower 
SHBG levels compared to control women (Table 2).
Vascular ultrasonographic parameters are reported in 
Table 3. Women with PCOS showed a significant higher 
anteroposterior diameter of the abdominal aorta compared 
to control women, and a tendency to an increase in carotid 
and femoral IMT. This result was confirmed (p = 0.024) by 
multivariate analysis of covariance correcting for systolic and 
diastolic blood pressure and WHR. When BMI was added 
as covariate, the comparison lacked statistical significance 
due to the large difference in BMI between the control and 
PCOS groups.
Discussion
The most original result of the present study is that the 
anteroposterior diameter of the abdominal aorta is signifi-
cantly higher in women with PCOS than in normal weight 
and fertile women.
It has been recently shown that age,21 BMI,21 and intraab-
dominal fat (measured by ultrasound)22 are significantly 
associated with increasing aortic diameter independent of 
other cardiovascular disease risk factors. Since PCOS and 
control women were similar in age in this study, whereas 
BMI and WHR were higher in women with PCOS, it may 
well be that BMI and abdominal fat are responsible for 
the higher anteroposterior diameter of the abdominal aorta 
in women with PCOS. In fact, anteroposterior diameter 
did not maintain a significant relationship when BMI was 
considered as covariate during multivariate analysis of 
covariance.
This study confirms that women with PCOS are at higher 
cardiovascular risk compared with control women, but it 
does not confirm the previously shown significant increase 
of common carotid artery IMT in women with PCOS.15–17 It 
is possible that the limited number of patients in our study 
may be responsible for the lack of a significant difference 
in this parameter. However, it is noteworthy that this study 
examined young PCOS women, 17 to 27 years old, with a 
mean age of 22 years. Since most previous studies investi-
gating the relationship between PCOS and cardiovascular 
risk examined women with a mean age around 40 years,15–17 
it may well be that the age of women in our study was too 
low to show artery thickening and differences between the 
groups. This may explain the lack of a significant difference 
in the common femoral artery IMT between women with 
and without PCOS.
Our findings also show that the increase of the anteropos-
terior diameter of the abdominal aorta is the earliest arterial 
alteration in women with PCOS, thus preceding the IMT of 
other arteries such as common carotid arteries and common 
femoral arteries. These results are in line with a recent paper 
by Allison and colleagues.21
According to previous studies, BMI, abdominal fat 
accumulation, insulin, total cholesterol, LDL cholesterol, 
triglyceride, and apo B levels were higher in PCOS patients 
compared to normal weight women.6–14
Conclusion
Anteroposterior diameter of the infrarenal abdominal aorta, 
but not IMT of common carotid arteries or common femoral 
arteries, is higher in patients with PCOS than in normal 
weight and fertile women, thus preceding the thickening 
of other arteries. However, this alteration seems to be due 
to body weight secondary to PCOS and not due to PCOS 
per se.
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